Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK

Multi-cancer early detection (MCED) next-generation-sequencing blood tests represent a potential paradigm shift in screening.We estimated the impact of screening in the US and UK. We used country-specific parameters for uptake, and test-specific sensitivity and false-positive rates for current screening: breast, colorectal, cervical and lung (US only) cancers. For the MCED test, we used cancer-specific sensitivities by stage. Outcomes included...